Navigation Links
Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting

MONTREAL, Nov. 25 /PRNewswire/ - Aegera Therapeutics Inc. today announced that data from its phase 1/2 clinical trial of the XIAP antisense oligonucleotide, AEG35156, will be highlighted in an oral presentation at the 50th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, on December 9, 2008.

The presentation is entitled "Phase I/II Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Idarubicin and Cytarabine in Patients with Relapsed/Refractory AML". The trial was an open label, multi-center study evaluating the safety and efficacy of AEG35156 in combination with chemotherapy in AML patients in first relapse after a short initial CR or with primary refractory disease. A total of 51 patients were enrolled in the study. The results demonstrate that AEG35156 is well tolerated at 350 mg/m2 in combination with idarubicin and cytarabine. The results also support the finding that AEG35156 combination therapy may induce high response rates in AML patients not responding to frontline induction therapy. Updated results on additional patients will be presented at the ASH Annual Meeting.

The study's principal investigator, Dr. Aaron D. Schimmer, M.D., Ph.D. of the Princess Margaret Hospital in Toronto will present the results of this study at the ASH session entitled "Acute Myeloid Leukemia - Therapy, Excluding Transplantation".

In addition, PD data from the same study will be presented by Dr. Carter Bing of the MD Anderson Cancer Center in a poster on December 7 under the title "Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML".

Details of each of these presentations are listed below.

2008 ASH Annual Meeting ASH - Oral Presentation

Title: Phase I/II Trial of the XIAP Antisense Oligonucleotide (AEG35156)

in Combination with Idarubicin and Cytarabine in Patients with

Relapsed/Refractory AML

Session Name: Acute Myeloid Leukemia - Therapy, Excluding Transplantation

Session Date: Tuesday, December 9th, 2008 Presentation Time: 7:45 AM

Session Location: Moscone Center, Room 3020-3022-3024 - West

2008 ASH Annual Meeting - Poster Presentation

Title: Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense

Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients

with Relapsed/Refractory AML

Abstract: #1943, Poster Board # II-37

Session Date: Sunday, December 7th, 2008

Session Time: 6:00 PM - 8:00 PM

Session Location: Moscone Center, Hall A

About AEG35156

AEG35156, a second generation antisense which targets XIAP, is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy. Aegera's published data with AEG35156, both in vitro and in vivo, strongly supports this hypothesis, and validates XIAP as a novel oncology drug target. The activity of AEG35156 is currently being explored, in combination, or as a monotherapy, in the following indications: acute myeloid leukemia, non-small cell lung cancer, hepatocarcinoma, and chronic lymphocytic leukemia and indolent B-cell lymphomas. The latter study is being conducted with the financial and scientific support of the Leukemia and Lymphoma Society through their innovative Therapy Acceleration Program.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. In addition to AEG35156, Aegera has three additional programs in clinical development for the treatment of cancer and neuropathic pain. Details of these programs can be found on Aegera's website at

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
2. Aegera Therapeutics welcomes two experienced executives to its board of directors
3. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
4. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
5. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
6. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
7. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
8. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
9. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
10. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
11. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):